104
Participants
Start Date
December 2, 2017
Primary Completion Date
December 4, 2017
Study Completion Date
December 31, 2017
ICI
Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris
Institute of Cardiometabolism and Nutrition, France
OTHER
Vanderbilt University
OTHER
Vanderbilt University Medical Center
OTHER
Groupe Hospitalier Pitie-Salpetriere
OTHER